Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even ...

Layoffs have become a common business practice, but research shows long-term performance actually declines after layoffs.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...

GAMMA Investing LLC increased its stake in Eli Lilly by 25.8%, now holding 18,000 shares valued at nearly $15 million. This ...

A new injectable weight loss treatment from the maker of Ozempic and Wegovy delivered 23% weight loss in trials, according to findings published in the New England journal and medicine. Dr ...